Metastatic Solid Tumor
Conditions
Brief summary
This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer \[18F\]AlF-RESCA-IL2 in patients prior to and during treatment.
Interventions
OTHER[18F]AlF-RESCA-IL2 PET scan
Patients will undergo \[18F\]AlF-RESCA-IL2 PET imaging twice; the first \[18F\]AlF-RESCA-IL2 PET scan will be performed at baseline, before starting therapy. The second \[18F\]AlF-RESCA-IL2 PET scan will be performed after 2 weeks of treatment
Sponsors
University Medical Center Groningen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years at the time of signing informed consent. 2. Patients with histologically confirmed diagnosis of locally advanced or metastatic solid cancer, eligible for ICI therapy as part of routine care. 3. At least 1 lesion that is accessible per investigator's assessment and eligible for biopsy according to standard clinical care procedures. 4. Measurable disease, as defined by standard RECIST v1.1. Previously irradiated lesions should not be counted as target lesions except for lesions that have progressed after radiotherapy. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Life expectancy ≥ 12 weeks. 7. Signed informed consent. 8. Willingness and ability to comply with all protocol required procedures. 9. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception (i.e., one that results in a low failure rate (\< 1% per year) when used consistently and correctly)).
Exclusion criteria
1. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to \[18F\]AlF-RESCA-IL2 injection. 2. Evidence of an active infection that requires systemic antibiotics within 2 weeks prior to \[18F\]AlF-RESCA-IL2 injection. 3. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of \[18F\]AlF-RESCA-IL2, or that may affect the interpretation of the results or render the patient at high risk from complications. 4. Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent. 5. Sponsor employee/member of the clinical site study team and/or his or her immediate family 6. Pregnant or lactating females. 7. Concurrent use of systemic corticosteroids \> 10 mg daily prednisone equivalent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Non-displaceable binding potential (BPND) | 2 years | To evaluate the pharmacokinetic behaviour of 18F-AIF-RESCA-IL2 through activity in venous blood samples, dynamic imaging, and pharmacokinetic modeling. |
| Incidence of adverse events related to [18F]-AlF-RESCA-IL2 administration as assessed by CTCAE v5.0 | 2 years | Safety assessment through summaries of adverse events, changes in laboratory test results (if evaluation is indicated) and changes in vital signs. Adverse event data will be recorded and summarized according to NCI CTCAE v5.0 |
| Total volume of distribution (VT) of the tracer in the tumour | 2 years | To evaluate the pharmacokinetic behaviour of 18F-AIF-RESCA-IL2 through activity in venous blood samples, dynamic imaging, and pharmacokinetic modeling. |
| Biodistribution of [18F]-AlF-RESCA-IL2 | 2 years | Evaluation of \[18F\]AlF-RESCA-IL2 biodistribution in cancer patients on the PET images by measuring standardized uptake values in tumours, healthy tissues and organs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of 18F-AlF-RESCA-IL2 PET measurements with radiologic response to treatment, according to (i)RECIST v1.1 criteria. | 2 years | Response to therapy will be assessed according to the RECIST or iRECIST guidelines. These results will be compared with imaging tracer standardized uptake value (SUV) in defined volumes of interest (VOIs) of tumor lesions on the PET scan images. |
| Assessment of changes in tumour and normal organ tracer uptake after 2 weeks of treatment, expressed as standardized uptake values. | 2 years | Patients will undergo a PET scan at baseline and another one during treatment. tracer uptake will be quantified and expressed as standardized uptake value (SUV) in defined volumes of interest (VOIs) for both scans. The results of both PET scans will be compared to assess changes in imaging tracer uptake over time. |
| Correlation of 18F-AlF-RESCA-IL2 uptake in tumours, with T cell infiltration in tumour biopsy samples, as determined by IHC. | 2 years | Results of immunohistochemical (IHC) scoring of immune cell IL-2R expression will be described as a semi-quantitative score using the percentage of positive cells (continuous variable), intensity and pattern of staining (discrete variable). These IHC results will be compared with imaging tracer standardized uptake value (SUV) in defined volumes of interest (VOIs) of tumor lesions on the PET scan images. |
Countries
Netherlands
Outcome results
None listed